Health
FDA grants rare disease designations to investigational brain tumor drug – News-Medical.Net
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahom…
Reviewed by Emily Henderson, B.Sc.Sep 2 2020
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
DIPG is a fast-growing pediatric cancer that starts in the brain stem. It is one of several sub-categories of malignant gliomas,…
-
Noosa News19 hours agoQueensland teachers strike for second time this year after rejecting 8 per cent wage rise
-
General19 hours agoVictorian government blocked fire service from pursuing US giant over PFAS contamination
-
General23 hours agoXi Jinping tells Donald Trump Taiwan’s ‘return to China’ is key to international post-war order
-
General22 hours agoLabor path to pass nature laws in last week narrows